Skip to content
DataLookout
Menu

NCT06745882

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 15 versions: 13 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 8 → 11 locations
    • Eligibility criteria expanded, about 28 words
    • Collaborators: details revised at 1 of 3 entries
  2. Minor Study sites: 7 to 8v14
  3. Minor Study sites: 6 to 7v13
  4. Minor Study sites: 5 to 6v12
  5. Minor Study sites: 4 to 5v11
Show 7 earlier versionsHide 7 earlier versions
  1. Minor Study sites: 2 to 4v10
  2. Minor Study sites: 1 to 2v9
  3. Notable Start date: Jan 21, 2025 to Jun 13, 2025v8
  4. Minor Start date changed from estimate of Jan 2025 to Jan 21, 2025v5
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v4
  6. Notable Enrollment target: 24 to 318v3
  7. Minor Eligibility criteria shortened, about 412 wordsv2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Cohort 1: Real World Overall Survival (rwOS)
Timeframe: Up to 36 Months
Cohort 2 Arm A: Progression Free Survival (PFS)
Timeframe: Up to 36 Months
Cohort 2 Arm B: Progression Free Survival (PFS)
Timeframe: Up to 36 Months

Secondary (3)

Cohort 1: Baseline ctDNA
Cohort 2: Arm A and Arm B Objective Response Rate (ORR)
Cohort 2: Arm A and Arm B Overall Survival (OS)

Arms and interventions

Cohort 1Experimental

Non-interventional prospective cohort and participants will receive standard of care pembrolizumab with or without chemotherapy.

Cohort 2: arm AExperimental

Cohort 2 Arm A will enroll patients with NSCLC with PD-L1 TPS status ≥1% and ctDNA tumor fraction low/negative and be treated with pembrolizumab monotherapy.

Cohort 2: arm BExperimental

Cohort 2 Arm B will enroll patients with NSCLC with any PD-L1 status and ctDNAtumor fraction intermediate/high -OR- PD-L1 TPS\<1% and any ctDNA level treated with chemotherapy plus pembrolizumab.

Drugs: Cisplatin, Carboplatin, Pemetrexed, Pembrolizumab, Abraxane, Paclitaxel

Sites

11 sites in 1 country